Ursobil HT

Quick links to important sections

Ursobil HT

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ursobil HT

The following section defines the identity and core classification of the medicine Ursobil HT (Ursodiol), its composition, and its general purpose.

Property Description
Active ingredient Ursodiol (Ursodeoxycholic acid, UDCA)
Form Oral dosage form (Hard capsules or film-coated tablets)
Pharmacological class Choleretic agent, Gallstone solubilizing agent, Cytoprotective agent
General purpose To modulate bile composition and protect liver cells
Origin Semi-synthetic derivative of a naturally occurring bile acid

Ursobil HT: Identity and Core Classification

Ursobil HT is a prescription-only oral medication classified as a choleretic agent and a gallstone solubilizing agent. Its single active ingredient is Ursodiol, chemically known as Ursodeoxycholic acid (UDCA). This classification describes its core therapeutic role in the biliary system. The medicine belongs to a specialized group of bile acid therapies; its structure enables it to act as a cytoprotective agent by stabilizing cell membranes.

Composition, Form, and Origin of Ursodiol

The Ursobil HT preparation is a single active ingredient product designed for the oral route, available in precise dose units as hard capsules or film-coated tablets. Ursodiol itself is a semi-synthetic derivative of a naturally occurring secondary bile acid. A key feature is its hydrophilic nature, which allows it to naturally integrate into the bile acid pool to compete with and displace more hydrophobic and potentially harmful bile acids. This chemical substitution forms the basis for maintaining a healthier bile environment.

General Purpose: Supporting the Liver and Bile System

The general therapeutic purpose of Ursobil HT is to support the overall health and functionality of the liver and gallbladder system. Its primary goal is to aid in the solubilization of cholesterol that forms certain types of gallstones by reducing the cholesterol saturation level in the bile. Furthermore, its function as a cytoprotective agent helps preserve the structural integrity of liver cells and the lining of the bile ducts, supporting appropriate bile flow and reducing cellular stress.

Regulatory References

  1. NIH MedlinePlus, Drugs: Ursodiol

What side effects are possible with Ursobil HT?

Possible Side Effects and Safety Information

This section outlines the officially documented safety profile of Ursobil HT, detailing known adverse reactions and important safety restrictions as organized by governmental regulatory agencies.

Frequency-Classified Adverse Reactions

The most frequently reported side effects are primarily related to the digestive system:

  • Common (may affect up to 1 in 10 people):
    • Diarrhea or loose stools (often reported as dose-dependent)
    • Right upper abdominal pain or general abdominal discomfort

System-Organ Classes and Serious Events

Adverse reactions have been reported across several system-organ classes, including Gastrointestinal disorders, Hepatobiliary disorders, and Skin and subcutaneous tissue disorders. Serious adverse events reported in regulatory documents include:

  • Decompensation of liver cirrhosis, reported in isolated cases of end-stage Primary Biliary Cirrhosis.
  • Jaundice (yellowing of the skin or eyes) or the aggravation of pre-existing jaundice.
  • Drug hypersensitivity reactions (e.g., facial swelling, hives, laryngeal swelling).

Safety Restrictions and Monitoring

Regulatory information defines specific limitations and monitoring requirements:

  • Contraindications: Ursobil HT must not be used in patients with complete biliary obstruction, acute cholecystitis, or in those who require cholecystectomy.
  • Liver Monitoring: Official labeling requires periodic monitoring of liver function tests (including gamma -GT, Alkaline phosphatase, AST, and ALT) and bilirubin levels. This is intended for the early detection and management of possible deterioration of liver function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Ursobil HT (Ursodiol) establishes that serious systemic toxicity following an acute overdose is considered unlikely to occur. This classification is based on pharmacological data indicating that the intestinal absorption of Ursodeoxycholic acid decreases substantially as the dose increases, effectively limiting the amount of the active ingredient that enters systemic circulation.

The most likely clinical manifestation documented by regulatory authorities for a severe over-exposure is diarrhea. This gastrointestinal effect is the primary documented sign observed during overdose scenarios.

When to Seek Urgent Help

Immediate medical attention is mandated for any suspected overdose or if an unusually high amount of the medicine has been taken. Medical advice must also be sought if persistent diarrhea occurs, as regulatory guidance requires dose reduction or discontinuation of the therapy under such circumstances.

Officially Documented Management and Monitoring

Overdose management is primarily symptomatic, focusing on the treatment of diarrhea. Official procedures described in regulatory documents may include the use of ion-exchange resins which are intended to bind excess bile acids in the intestine to facilitate their removal from the body. Following an overdose event, liver function monitoring is officially required. No specific pharmaceutical antidote for Ursodiol is currently known or documented in official labeling.

Therapeutic Uses of Ursobil HT

What Ursobil HT treats: Main Uses and Benefits

Ursobil HT is applied across domains where additional symptomatic support is needed for conditions linked to the biliary system. Its primary therapeutic uses include the long-term management of Primary Biliary Cholangitis (PBC), the dissolution of small cholesterol gallstones, and prevention of gallstone formation in high-risk scenarios.

Symptomatic Relief and Contextual Use

The medication is commonly used to help manage symptoms related to cholestasis, such as distressing itching (pruritus), and is relevant for managing elevated liver enzyme levels. This use is particularly relevant in conditions where functional stability becomes affected, which is consistent with the goal of chronic disease support. It is also applied when supportive symptom management is appropriate for patients experiencing recurrent pain (biliary colic) associated with gallstones.

“This therapeutic approach is primarily relevant for conditions involving systemic imbalance where supportive relief is needed.”

In clinical practice, it is often used during the chronic phases of PBC to help manage the rate of disease activity. It is also relevant when a non-invasive approach is sought for stone management, and in prophylactic scenarios following bariatric surgery or during rapid weight loss. This prophylactic use supports patients during this phase by helping to mitigate the risk of developing gallstone-related symptoms. Ursobil HT contributes to the support of liver function over time and supports general well-being during symptomatic phases.


Quick Fact: Relief for Cholestatic Pruritus The medication is commonly used to address symptoms that interfere with daily comfort, such as the persistent and generalized itching associated with impaired bile flow.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Ursobil HT is officially indicated for use in adults with Primary Biliary Cholangitis (PBC) who do not have decompensated cirrhosis. It is also designated for adults requiring dissolution or prevention of certain types of gallstones.

Contraindicated Populations

Use of Ursobil HT is contraindicated (must not be used) in several specific patient populations, according to official regulatory labeling. These include individuals with known hypersensitivity to ursodiol or other bile acids, and those with a complete obstruction of the biliary tract. The medicine must not be used in patients with radio-opaque calcified gallstones or a non-functioning gallbladder. It is also contraindicated in acute conditions such as acute cholecystitis or cholangitis.

Age and Physiological Restrictions

  • Pediatric Use: Use is approved for children aged 6 years and older for hepatobiliary disorders associated with cystic fibrosis. Safety and effectiveness for gallstone dissolution are generally not established in children.
  • Pregnancy and Lactation: Use during pregnancy is restricted and recommended only when clearly needed. Women of childbearing potential must use reliable contraception during therapy. Caution is advised when administering the medicine to a nursing mother.

What should I know about interactions with other medicines?

Ursobil HT (ursodiol) can interact with certain other medicinal products, which may reduce its effectiveness. These interactions fall into two main categories: those that decrease the drug's absorption and those that oppose its intended therapeutic action.

Reduced Absorption

Bile Acid Sequestering Agents such as cholestyramine and colestipol may reduce the amount of Ursobil HT absorbed by the body, which can interfere with its action. Similarly, Aluminum-based Antacids (e.g., aluminum hydroxide) can also bind to bile acids and are expected to interfere with absorption in the same way. To manage this interaction, a specific time interval, typically several hours, must separate the administration of Ursobil HT and these agents.

Counteracted Effectiveness

Products that can increase the secretion of cholesterol by the liver may directly counteract the beneficial effects of Ursobil HT. These include certain hormonal products like estrogens and oral contraceptives, as well as some lipid-lowering drugs such as clofibrate. Combining Ursobil HT with these medicinal products may promote the formation of cholesterol gallstones, thereby hindering the intended goal of therapy. Patients should inform their healthcare provider of all co-administered medicines, vitamins, and supplements.

Mechanism of Action

How Ursobil HT Works: Mechanism of Action

Ursobil HT (Ursodeoxycholic Acid, UDCA) exerts its action primarily by altering the physicochemical properties of the bile acid pool. As a highly hydrophilic bile acid, UDCA preferentially accumulates and displaces more toxic, hydrophobic bile acids from the enterohepatic circulation. This molecular substitution modulates membrane integrity and protects liver cell components, including hepatocytes and cholangiocytes, from the detergent effects of endogenous bile acids. This process is categorized as cytoprotection.

UDCA also acts as an inhibitor in two key areas of cholesterol flux: it reduces the secretion of cholesterol from the liver into the bile and decreases its reabsorption in the intestine. This dual inhibition reduces the cholesterol saturation of the bile, thereby promoting cholesterol solubilization. Furthermore, UDCA modulates key nuclear receptors, such as the Farnesoid X Receptor (FXR), affecting the regulatory pathways of bile acid and lipid homeostasis and increasing bile flow (choleretic effect). The combined molecular and cellular effects result in a less toxic bile composition and reduced cellular injury.

Dosage and Administration Information

How to Use Ursobil HT

Ursobil HT (Ursodiol) is an oral medication that is administered exclusively by the oral route. It is available in various official strengths, including 250 mg and 500 mg tablets, and 200 mg and 300 mg capsules. The medication's general use is structured around specific weight-based dosing for adults and children, and the total daily dose is typically divided into two to four administrations throughout the day.


Official Administration Schedule

Use Case Dosing Pattern (Adults) Frequency and Timing
Primary Biliary Cholangitis (PBC) 13 mg/kg/day to 15 mg/kg/day 2 to 4 divided doses daily
Gallstone Dissolution 8 mg/kg/day to 10 mg/kg/day 2 to 3 divided doses daily; final dose often at bedtime

Procedural Administration and Duration

For proper administration, Ursobil HT must be taken with food to enhance drug absorption and facilitate its optimal distribution within the bile acid pool. Scored tablets can be split to achieve the required dosage, but the segments must be swallowed whole with water and not chewed.

Treatment for conditions like PBC is generally established as long-term therapy. For gallstone dissolution, the course of use is often prolonged, requiring many months, and must continue for at least three to four months after the complete radiological disappearance of the stones to ensure treatment success.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ursobil HT (Ursodiol)

Evidence for Use in Primary Biliary Cholangitis (PBC)

The research available for Ursobil HT in managing Primary Biliary Cholangitis (PBC), a chronic liver condition, is supported by controlled clinical trials and large-scale, long-running observational studies. Short-term Randomized Controlled Trials (RCTs) were conducted to monitor the timelines over which changes in liver function markers, such as bilirubin and alkaline phosphatase (ALP), were monitored. Researchers monitored these biochemical shifts as a way to understand later disease patterns.

For long-term understanding, research heavily relied on large international patient registries and observational cohort studies, some of which monitored patients for a decade or more. These studies explored whether the treatment was observed in patients with differences in critical long-term outcomes, including overall survival and the need for liver transplantation. Findings describe patterns showing that adult patients who showed a specific change in their biochemical markers early in treatment often were associated with different measurements in long-term clinical outcomes. However, a proportion of patients are observed to have an incomplete response in their biochemical markers.

Evidence for Use in Cholesterol Gallstone Management

Research has explored two distinct scenarios related to gallstones: studies of gallstone dissolution and studies of prevention in specific high-risk scenarios. For gallstone dissolution, controlled clinical trials (RCTs) monitored the rate of gallstone clearance in adult study populations with small, non-calcified (radiolucent) cholesterol gallstones. Research describes that the highest rates of dissolution measurement were reported for smaller stones. Studies observed that the measured dissolution often took a prolonged period of continuous treatment, often lasting many months.

For prevention, placebo-controlled trials were conducted in high-risk groups undergoing rapid weight loss. The data show patterns related to a difference in the incidence of new stone formation over the short-term follow-up period during this phase of rapid weight loss.

Areas of Research Uncertainty and Gaps

Research continues to explore why a proportion of patients with PBC show an incomplete biochemical response to the treatment. For gallstone dissolution, the underlying factors driving the noted rate of stone recurrence following treatment are not fully established, and comparative evidence is lacking for managing this long-term risk. Additionally, follow-up durations were limited in many of the initial, strictly controlled trials.

Key Studies & References

  1. Pruritus in cholestasis, and its management.
  2. Ursodiol Drug Information (MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Ursobil HT (FAQ)


Q: How quickly should I notice any change after starting Ursobil HT?

According to official product information, changes may be gradual. For conditions like gallstone dissolution, the treatment often requires continuous use for many months. Biochemical changes are often monitored by a healthcare provider over time; initial progress may be assessed after approximately 3 to 6 months of continuous use.

Q: Is it normal to feel a little nauseous when you first start taking Ursobil HT?

Nausea is a reported adverse reaction. Official prescribing information notes that some people may experience nausea or vomiting, especially when first starting treatment. Persistent or severe symptoms warrant discussion with a healthcare provider.

Q: Does Ursobil HT help with weight loss, or is that a myth?

Ursobil HT is not officially indicated for the purpose of weight loss. However, official information states that it is sometimes prescribed to prevent the formation of gallstones in individuals who are undergoing rapid weight loss. Weight changes are also noted as an adverse effect of unknown incidence.

Q: Can Ursobil HT cause any changes to my skin or complexion?

Serious but uncommon events reported in regulatory documents include jaundice, which is a yellowing of the skin or eyes. Furthermore, drug hypersensitivity reactions, which may involve a rash or hives on the skin, have also been reported.

Q: Are there any specific vitamins or supplements that shouldn't be taken with Ursobil HT?

Regulatory information specifically warns that certain medicines and hormonal products can interfere with Ursobil HT's effectiveness. While specific vitamins are not detailed, patients are generally advised to inform their healthcare provider of all co-administered supplements, as some supplements may contain substances that could affect the medication’s absorption or effectiveness.

Q: What happens if I accidentally miss a dose of Ursobil HT?

General instructions for a missed dose often suggest taking it as soon as it is remembered. If it is near the time of the next scheduled dose, skipping the missed dose and continuing with the regular schedule is commonly recommended. It is generally advised not to take a double dose to make up for a missed dose.

Q: Is Ursobil HT safe for older adults, or are there more risks?

Official information indicates that appropriate studies have not shown unique, specific problems that would prevent its use in older adults. However, older patients may be more sensitive to the medication's effects, and dosage is determined carefully by a healthcare provider.

Q: Can people with diabetes safely take Ursobil HT?

Hyperglycemia (elevated blood sugar) has been reported as a less common side effect of ursodiol. Patients with diabetes are typically advised to discuss their condition and any potential for metabolic changes with a healthcare provider before starting therapy.

Q: Does Ursobil HT affect how birth control pills work?

Official prescribing information does not list Ursobil HT as reducing the effectiveness of birth control pills. However, products containing hormones, such as oral contraceptives, may counteract the therapeutic effect of Ursobil HT by potentially increasing the secretion of cholesterol into the bile.

Q: Why does the packaging of Ursobil HT mention the need for regular checkups?

Official safety restrictions require periodic monitoring of liver function tests and bilirubin levels. This is done to help detect any changes or deterioration in liver function early during treatment.

Q: Is it true that Ursobil HT can help improve liver enzyme levels?

The official label requires monitoring of liver enzyme levels, such as AST and ALT, which are used as markers of liver function. Monitoring these enzymes is a common way for healthcare providers to assess the therapeutic response to the medication.

Q: Can people with kidney problems take Ursobil HT safely?

Official monographs state that there are no specific dose adjustments recommended at this time for patients with impaired kidney function. Any use in this population is determined by a healthcare provider.

Q: What's the maximum amount of time someone usually takes Ursobil HT?

For Primary Biliary Cholangitis (PBC), treatment is generally established as long-term therapy. For gallstone dissolution, the course of therapy is highly variable, but typically requires many months, and must continue for at least three to four months after the stones have fully fully disappeared.

Q: Do children ever get prescribed Ursobil HT for bile duct issues?

Yes, official regulatory labeling approves the use of Ursobil HT for children aged 6 years and older to treat hepatobiliary disorders that are associated with cystic fibrosis.

Q: Can Ursobil HT cause hair thinning or changes?

Alopecia, which is the medical term for hair loss or thinning, has been reported as an adverse effect in clinical trials, though typically with a low incidence.

Q: Can Ursobil HT cause changes in mood or sleep patterns?

Official regulatory documents report insomnia, or difficulty sleeping, as a side effect that was observed in clinical trials. Changes in mood are not specifically listed in the common adverse reaction summaries.

Q: What evidence supports the use of Ursobil HT in treating primary biliary cholangitis (PBC)?

The use of the medicine for PBC is supported by controlled clinical trials. The evidence also includes large-running observational studies that explore long-term patient outcomes, such as the need for liver transplantation or overall survival.

Q: Are there specific food types that are better or worse when taking Ursobil HT?

The primary instruction is to take the medicine with food to ensure optimal absorption. The official information does not list specific food types to avoid, but it notes that certain lipid-lowering drugs may counteract its effectiveness.

Q: Do people who take Ursobil HT usually feel better right away or is it a gradual improvement?

The therapeutic effect of this medication is typically a gradual process that involves measurable biological changes monitored by a doctor. For example, the treatment for gallstones often requires many months of continuous use before positive change is observed.

Q: Is it possible for Ursobil HT to cause diarrhea, and if so, how is that managed?

Diarrhea or loose stools are one of the most commonly reported side effects, which may be related to the dose. While the official documents report this side effect, they do not provide specific management guidance for the patient.

Q: How long after stopping Ursobil HT can the symptoms return?

For gallstone dissolution, regulatory information notes that recurrence of gallstones has been observed in up to 50% of patients within five years after complete dissolution and treatment cessation.

Q: Are there reports of Ursobil HT causing allergic reactions, and what are the signs?

Yes, drug hypersensitivity reactions are reported as a serious adverse event. Signs that may occur include facial swelling, hives on the skin, and laryngeal swelling.

Q: Is it safe to crush or chew Ursobil HT tablets if swallowing is difficult?

Official administration instructions specify that any segments of scored tablets must be swallowed whole with water and must not be chewed. This is typically required to avoid a bitter taste and ensure proper delivery of the medication.

How should Ursobil HT be stored and disposed of?

How to Store and Dispose of Ursobil HT

The storage and disposal of Ursobil HT (Ursodiol) are defined by regulatory requirements to ensure its stability and safety.


Storage Conditions

Ursobil HT must be stored at Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F and 77 F). The medication must be protected from excessive moisture and kept in a tightly closed container to preserve its integrity. It is mandatory to keep the product out of the reach of children.


Disposal Instructions

Expired or unused Ursobil HT must be disposed of according to local regulations. The official guidance specifies that the medicine should not be flushed down the toilet or poured into a drain; instead, it should be utilized through a medicine take-back program when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursobil HT found in:

A-Z Index: